Literature DB >> 19784068

Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.

S Bettuzzi1, P Davalli, S Davoli, O Chayka, F Rizzi, L Belloni, D Pellacani, G Fregni, S Astancolle, M Fassan, A Corti, R Baffa, A Sala.   

Abstract

ApoJ/Clusterin (CLU) is a heterodimeric protein localized in the nucleus, cytoplasm or secretory organelles and involved in cell survival and neoplastic transformation. Its function in human cancer is still highly controversial. In this study, we examined the prostate of mice in which CLU has been genetically inactivated. Surprisingly, we observed transformation of the prostate epithelium in the majority of CLU knockout mice. Either PIN (prostate intraepithelial neoplasia) or differentiated carcinoma was observed in 100 and 87% of mice with homozygous or heterozygous deletion of CLU, respectively. Crossing CLU knockout with TRAMP (prostate cancer prone) mice results in a strong enhancement of metastatic spread. Finally, CLU depletion causes tumourigenesis in female TRAMP mice, which are normally cancer free. Mechanistically, deletion of CLU induces activation of nuclear factor-kB, a potentially oncogenic transcription factor important for the proliferation and survival of prostate cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19784068     DOI: 10.1038/onc.2009.286

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse.

Authors:  Erin M Goodwin; Qing Zhong; Catherine S Abendroth; Lindsay K Ward-Kavanagh; Todd D Schell; Timothy K Cooper
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

2.  Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kolja Wawrowsky; Yuji Tani; Anat Ben-Shlomo; Vladimir Ljubimov; Adam Mamelak; Serguei Bannykh; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2012-10-09

3.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Authors:  Twishi Gulati; Cheng Huang; Franco Caramia; Dinesh Raghu; Piotr J Paul; Robert J A Goode; Simon P Keam; Scott G Williams; Sue Haupt; Oded Kleifeld; Ralf B Schittenhelm; Cristina Gamell; Ygal Haupt
Journal:  Mol Cell Proteomics       Date:  2018-02-20       Impact factor: 5.911

4.  Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer.

Authors:  Anna A Powolny; Ajay Bommareddy; Eun-Ryeong Hahm; Daniel P Normolle; Jan H Beumer; Joel B Nelson; Shivendra V Singh
Journal:  J Natl Cancer Inst       Date:  2011-02-17       Impact factor: 13.506

5.  Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.

Authors:  Wojciech Mydlarz; Mamoru Uemura; Sun Ahn; Patrick Hennessey; Steven Chang; Semra Demokan; Wenyue Sun; Chunbo Shao; Justin Bishop; Julie Krosting; Elizabeth Mambo; William Westra; Patrick Ha; David Sidransky; Joseph Califano
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

6.  Chemoprevention of prostate cancer by d,l-sulforaphane is augmented by pharmacological inhibition of autophagy.

Authors:  Avani R Vyas; Eun-Ryeong Hahm; Julie A Arlotti; Simon Watkins; Donna Beer Stolz; Dhimant Desai; Shantu Amin; Shivendra V Singh
Journal:  Cancer Res       Date:  2013-08-06       Impact factor: 12.701

Review 7.  Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.

Authors:  Sohaib Al-Asaaed; Eric Winquist
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

8.  Lineage-specific restraint of pituitary gonadotroph cell adenoma growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Cuiqi Zhou; Anat Ben-Shlomo; Kolja Wawrowsky; Yoel Toledano; Yunguang Tong; Kalman Kovacs; Bernd Scheithauer; Shlomo Melmed
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

9.  Proapoptotic role of nuclear clusterin in brain.

Authors:  Nayoung Kim; Wan Sung Choi
Journal:  Anat Cell Biol       Date:  2011-09-29

10.  The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60.

Authors:  K-A Chaiwatanasirikul; A Sala
Journal:  Cell Death Dis       Date:  2011-10-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.